Company attributes
Other attributes
Cytek is main products are Aurora and Northern Lights systems. They are full-spectrum flow cytometers. With the help of these systems, scientists can analyze the characteristics of each individual cell — in 1 second, several tens of thousands of cells can be identified and studied. This technology helps to investigate the body's immune system and study its role in the fight against cancer, especially leukemia and lymphomas. It also allows you to detect signs of residual disease in those patients who have had organs transplanted. Cytometry is more effective than traditional microscopy, and allows you to speed up research many times.
As of March 31, 2021, Cytek Biosciences has already delivered 750 devices to 620 companies from around the world. This number includes pharmaceutical and biopharmaceutical companies, academic research centers and clinical research laboratories. Cytek systems are mainly used by scientists from the USA, China, Europe and Japan.
In 2020, the company recorded a net profit of $13.7 million and revenue of $92.8 million. The total amount of investments attracted by Cytek is $144.3 million.
The company estimates its potential market at $8 billion, noting that the overall clinical research market, according to MarketsandMarkets Research Private, Ltd., will grow from $16 billion in 2019 to $23 billion by 2024.
